Lv2
108 积分 2023-09-08 加入
Reactivities of N-Nitrosamines against Common Reagents and Reaction Conditions
1天前
已完结
Stereocontrolled First Generation Synthesis of RIPK1 Inhibitor GDC-8264
1个月前
已完结
Discovery of RMC-6291, a potent, orally bioavailable, covalent RAS(ON) G12C selective inhibitor
1个月前
已完结
Synthetic Approaches and Clinical Application of KRAS Inhibitors for Cancer Therapy
1个月前
已完结
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
1个月前
已完结
Discovery of novel small molecules targeting the USP21/JAK2/STAT3 axis for the treatment of triple-negative breast cancer
2个月前
已完结
N-Nitrosamine Drug Substance Related Impurities (NDSRIs) – A proposal for the addition of subcategories to Carcinogenic Potency Categorisation Approach categories 1 and 2 for NDSRIs with a molecular weight > 200 Da
3个月前
已完结
On the role of digital tools in nitrosamine risk assessment for drug substance and drug product manufacturing processes
3个月前
已完结
A comprehensive review of sources of nitrosamine contamination of pharmaceutical substances and products
3个月前
已完结
Confidence score calculation for the carcinogenic potency categorization approach (CPCA) predictions for N-nitrosamines
3个月前
已完结
皖公网安备34019202002308
